

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box Issue Fee
Assistant Commissioner for Patents
Washington, D.C. 20231

Match & Return

PATENT


000920US

7530

1/19/00

Box seg

356
H93
7/12/00



On 2/15/00

TOWNSEND and TOWNSEND and CREW LLP

By: Jan Kane

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GREGORY *et al.*

Application No.: 08/328,673

Filed: October 25, 1994

For: RECOMBINANT ADENOVIRAL
VECTOR AND METHODS OF
USE

Examiner: Guzo, David

Art Unit: 1636

Batch No.: D87

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

Box Issue Fee

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is submitted in response to the Response to Rule 312 Communication mailed November 17, 1999. In the Communication, the Examiner noted that the amendment to the specification at page 20 which was requested in Applicants' amendment filed August 17, 1998 could not be entered because the amendment would have rendered the sequence of SEQ ID NO:9 as presented in the specification different from that in the paper and computer-readable forms in the Sequence Listing. The Examiner indicated that entry of the amendment could not be entered until Applicants provide a new, complete Sequence Listing with the new SEQ ID NO:9. Accordingly, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing.